Collplant Biotechnologies, a regenerative and aesthetic medicine company, announced that the European Patent Office has allowed a patent application related to the company’s injectable fillings and the regenerative candidates of breast implants. Technologies are developing for use in aesthetic and reconstructive procedures.
The newly allowed patent application covers the soft tissue fillings of Collplant and its organ manufacturing technology associated with the iterative breast implants pipe. Specifically, the patent describes a biocompatible and degradable soft tissue implant in a 3D composted of a biopressed scaffolding and an injectable filling, both based on recombinant human collagen (Rhcolágen).
The patent is valid until 2041.
Injectable photocureable filling
The dermal photocurable filling and photocurable tissues based on Rhcolágen de Collplant is designed to provide tissue elevation, conformation and integration, while the regeneration of the promotion. The semiliquid filling is injected and then hardens in place using light lighting through the skin. According to the company, the photocration process can simplify injection in subcutaneous and supraperiosastal layers.
As the filling relegates, the formulation is intended to promote the regeneration of new tissues instead.
Regenerative Implant Program
The company is also advancing in the development of compound regenerative breast implants or rhcolágen derived from plants and other biocompatible materials. The implants are intended to support the natural regeneration of the tissue without triggering an immune response.
Collplant is positioning implants as a potential alternative for both cosmetic improvement and reconstructive surgeries, including applications after mastectomy.
Photo legend: A 200CC Commercial size breast implant (in front) of the Collplant regenerative program
Photo credit: Collplant biotechnologies